Zhou T, Ma C, Zhang H, et al. A retrospective comparative study on the prognostic impact of drug-coated balloon versus drug-eluting stent intervention in coronary heart disease. Chin J Adv Med Educ. 2023;46(01):4–7.

CAS  Google Scholar 

Liu MB, He XY, Yang XH, et al. Interpretation of Key Points from the “China Cardiovascular Health and Disease Report 2023.” Chin J Cardiovasc Med. 2024;29(4):305–24.

Google Scholar 

National Center for Cardiovascular Diseases. Report on Cardiovascular Health and Diseases in China 2023: An Updated Summary. Chin J Circul. 2024;39(7):625–60.

Google Scholar 

Chen Y, Wang C, Shang H, et al. Clinical practice guidelines in China. BMJ. 2018;360:5158.

Article  Google Scholar 

Gao XL, Yan Y. Case analysis in complex cardiovascular intervention: a study on postoperative care for coronary heart disease patients undergoing percutaneous coronary intervention. J Interv Radiol. 2024;33(09):1045.

Google Scholar 

Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndrome[guideline]. Edinburgh: SIGN, 2016 (SIGN Publications, 148). Available from: http://www.sign.ac.uk/sign-148-acute-coronary-syndrome.html Accessed 23 Oct 2024.

Vranckx P, Bueno H, Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.

Article  PubMed  Google Scholar 

Ling H, Wang B, Wu LX, et al. The evolution of everolimus-eluting stents. China Tissue Eng Res. 2019;23(6):978–84.

Google Scholar 

Gao WJ, Liu WJ, Ke YS. Evidence-based clinical research on the new-generation everolimus-eluting stent. Chin J Clin Pharmacol Ther. 2009;14(5):591–5.

Google Scholar 

Chen F, Gao YC, He JQ, et al. Effect comparison of domestic and imported rapamycin-eluting stents in treating coronary heart disease. Chin J Cardiol. 2006;34(11):994–6.

Google Scholar 

Zhou L, Guo Y, Wang W, et al. Clinical study on the efficacy of domestic Firebird2™ rapamycin-eluting stent versus imported everolimus resolute drug-eluting stent. Clin Med China. 2022;38(5):425–9.

Google Scholar 

von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.

Article  Google Scholar 

Ying X, et al. Determining sample size for pilot trials: a tutorial. BMJ. 2025;390:e083405.

Article  PubMed  Google Scholar 

Sun MZ, Hu SY, Sun ZJ. Research progress in coronary artery disease scoring systems. Chin J Mult Organ Dis Elderly. 2021;20(3):224–8.

Google Scholar 

Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.

Article  CAS  PubMed  Google Scholar 

Song CX, Zhou C, Zhang HJ. Progress in research drug eluting stents drug-loading and drug release kinetics. Chin J Med Instrum. 2018;42(3):193–7.

CAS  Google Scholar 

Li PM, Zhang M, Zhang XL. Research progress on pharmacokinetic influencing factors and therapeutic drug monitoring of Everolimus. China Pharm. 2013;24(46):4383–6.

Google Scholar 

von Birgelen C, van der Heijden LC, Basalus MW, et al. Five-year outcome after implantation of Zotarolimus- and Everolimus-Eluting Stents in randomized trial participants and nonenrolled eligible patients: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2017;2(3):268–76.

Article  Google Scholar 

Sotomi Y, Suwannasom P, Tenekecioglu E, et al. Differential aspects between cobalt-chromium Everolimus drug-eluting stent and absorb Everolimus bioresorbable vascular scaffold: from bench to clinical use. Expert Rev Cardiovasc Ther. 2015;13(10):1127–45.

Article  CAS  PubMed  Google Scholar 

Bi CH, Wei M, Shen H, et al. Effect comparison of domestic rapamycin eluting stent versus imported rapamycin eluting stent in patients with coronary atherosclerotic heart disease. Chin J Clin Med. 2016;23(6):744–8.

Google Scholar 

Wang ZC, Li XL, Chen Y, et al. Effect comparison of domestic Rapamycin and Ivermus or Zotamos drug eluting stents in the treatment of left main coronary artery opening and body lesions. China Modern Med. 2019;26(15):51–3.

CAS  Google Scholar 

Wu YQ, Yang LN, Shi YQ, et al. Curative effects and safety of zotarolimus-eluting stents and sirolimus-eluting stents on coronary heart disease: a meta-analysis. Clin Meta-anal. 2016;31(11):1254–60.

CAS  Google Scholar 

He N, Men P, Su S, et al. The effectiveness and safety of bioabsorbable polymer-coated platinum chromium everolimus-eluting stent for patients with coronary artery disease: a systematic review and meta-analysis. Chin J New Drugs. 2020;29(3):352–60.

Google Scholar 

Montone RA, Niccoli G, De Marco F, et al. Temporal trends in adverse events after Everolimus-Eluting bioresorbable vascular scaffold versus Everolimus-Eluting metallic stent implantation: a meta-analysis of randomized controlled trials. Circulation. 2017;135(22):2145–54.

Article  CAS  PubMed  Google Scholar 

Park KW, Kang SH, Velders MA, et al. Safety and efficacy of Everolimus- versus Rapamycin-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J. 2013;165(2):241-250.e4.

Article  CAS  PubMed  Google Scholar 

Byrne RA, Rossello X, Coughlan J, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.

Article  CAS  PubMed  Google Scholar 

Chinese Medical Association, and Editorial Board of Chinese Journal of Cardiology. Guidelines for the management of non-ST elevation acute coronary syndromes. Zhonghua Xin Xue Guan Bing Za Zhi. 2024;52(6):615–46.

Google Scholar 

Yu KW, Zeng QT. Interpretation of Guidelines for the management of non-ST elevation acute coronary syndromes. J Clin Cardiol. 2024;40(9):697–700.

Google Scholar 

U.S. Food and Drug Administration. Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. 2018–02–14. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed 23 Oct 2024.

Carter AA, Gomes Tcamacho X, et al. Risk of incident diabetes among patients treated with statins: Population based study. BMJ Clin Res Ed. 2013;346:f2610.

Google Scholar 

Gu YH, Ning HN, Wang JH, et al. Research progress on the risk factors, pathological mechanisms and precautions of statins-induced new-onset diabetes mellitus. Chin J Mod Appl Pharm. 2021;38(02):244–51.

Google Scholar